Home › Funds › PSP Research LLC › SYRE

PSP Research LLC position in SYRE

SPYRE THERAPEUTICS INC · Health Care

PSP Research LLC reported holding 4,000 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$355K, representing 0.19% of its reported portfolio and ranking #42 among its reported holdings. PSP Research LLC has disclosed SYRE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)4.00K sh
Reported value held$355.12K
Portfolio Weight0.19%
First reportedQ4 2025
Last changeNew

How PSP Research LLC's SYRE position evolved

PSP Research LLC first disclosed a stake in SYRE in Q4 2025 at 15,840 shares (US$519K). Across 3 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 4,000 shares valued at US$355K. Notable position changes include a 67% trim in Q1 2026 (shares rose 76% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 15.84K $518.92K New
Q1 2026 5.16K $260.22K Reduce
Q2 2026 4.00K $355.12K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 71 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →